On March 14, 2018 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that Dr. John Prendergast, Lead Independent Director of Heat Biologics, will present corporate highlights and positive interim data from its Phase 2 lung cancer clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb’s checkpoint inhibitor nivolumab (Opdivo) at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018 at 10AM China Standard Time (Press release, Heat Biologics, MAR 14, 2018, View Source [SID1234524970]). The conference will be held March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China. CHIPS is focused on building cross-border relationships between Chinese and Western Healthcare investors and companies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Heat Biologics’ presentation will not be webcast, but a copy may be found in the Investor Relations section of the Company’s website.